[1]李浩天,朱孝成,姚立彬,等.减重手术患者代谢健康型肥胖临床表型分析[J].医学信息,2024,37(05):123-127.[doi:10.3969/j.issn.1006-1959.2024.05.022]
 LI Hao-tian,ZHU Xiao-cheng,YAO Li-bin,et al.Clinical Phenotype Analysis of Metabolically Healthy Obesity in Patients Undergoing Bariatric Surgery[J].Journal of Medical Information,2024,37(05):123-127.[doi:10.3969/j.issn.1006-1959.2024.05.022]
点击复制

减重手术患者代谢健康型肥胖临床表型分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年05期
页码:
123-127
栏目:
论著
出版日期:
2024-03-01

文章信息/Info

Title:
Clinical Phenotype Analysis of Metabolically Healthy Obesity in Patients Undergoing Bariatric Surgery
文章编号:
1006-1959(2024)05-0123-05
作者:
李浩天朱孝成姚立彬
(1.徐州医科大学研究生院,江苏 徐州 221004;2.徐州医科大学附属医院胃肠外科,江苏 徐州 221002)
Author(s):
LI Hao-tianZHU Xiao-chengYAO Li-binet al.
(1.Graduate School,Xuzhou Medical University,Xuzhou 221004,Jiangsu,China;2.Department of Gastrointestinal Surgery,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221002,Jiangsu,China)
关键词:
减重手术代谢健康型肥胖代谢异常型肥胖危险因素
Keywords:
Bariatric surgeryMetabolically healthy obesityMetabolically unhealthy obesityRisk factors
分类号:
R656
DOI:
10.3969/j.issn.1006-1959.2024.05.022
文献标志码:
A
摘要:
目的 分析减重手术患者代谢健康型肥胖(MHO)的临床表型特点。方法 回顾性收集2019年1月-2022年6月在徐州医科大学附属医院减重代谢外科行减重手术的1220例(最终纳入1039例)肥胖症患者的临床资料,根据诊断标准分为代谢健康型肥胖组(MHO)、代谢异常型肥胖组(MUO),分析两组临床数据,并采用Logistic回归分析MHO的独立影响因素。结果 减重手术患者中MHO的占比为10.49%。MHO组年龄、收缩压、舒张压、空腹血糖、糖化血红蛋白、甘油三酯、谷草转氨酶、谷丙转氨酶、皮质醇均低于MUO组,高密度脂蛋白、总蛋白、白蛋白高于MUO组(P<0.05)。多因素Logistic回归分析显示年龄(OR<1,P<0.05)是MHO的独立危险因素,总蛋白水平(OR>1,P<0.05)是MHO的保护性因素。结论 MHO不应被误解为没有任何健康损害的肥胖人群,诊断为MHO的肥胖个体仍然是开始治疗的提示,但MHO患者是否需要进行减重代谢手术,以及进行手术的疗效仍需进一步研究。
Abstract:
Objective To analyze the clinical and phenotypic characteristics of metabolically healthy obesity (MHO) patients who underwent bariatric surgery.Methods Clinical data were retrospectively collected from 1220 obese patients (1039 patients were finally included) who underwent bariatric surgery at the Department of Metabolic and Bariatric Surgery, Xuzhou Medical University Hospital from January 2019 to June 2022. Patients were divided into metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) groups based on diagnostic criteria. Differences in clinical data between the two groups and factors affecting MUO were analyzed using logistic regression.Results The proportion of MHO in patients undergoing bariatric surgery was 10.49%. Age, systolic blood pressure, diastolic blood pressure, fasting blood glucose, glycosylated hemoglobin, triglyceride, aspartate aminotransferase, alanine aminotransferase and cortisol in MHO group were lower than those in MUO group, while high density lipoprotein, total protein and albumin were higher than those in MUO group (P<0.05). Multivariate logistic regression analysis showed that age (OR<1, P<0.05) was an independent risk factor for MHO, and total protein level (OR>1, P<0.05) was a protective factor for MHO.Conclusion MUO should not be misinterpreted as an obese population without any health impairment. Obese individuals diagnosed with MHO are still a sign to start treatment, but whether MHO patients need to undergo weight reduction metabolic surgery and the efficacy of performing surgery still needs further research.

参考文献/References:

[1]Bluher M.Obesity: global epidemiology and pathogenesis [J].Nat Rev Endocrinol,2019,15(5):288-298.[2]Jia WP,Liu F.Obesity: causes, consequences, treatments, and challenges [J].J Mol Cell Biol,2021,13(7):463-465.[3]Lin X,Li H.Obesity: Epidemiology, Pathophysiology, and Therapeutics [J].Front Endocrinol (Lausanne),2021,12(7):69-78.[4]Saxton SN,Clark BJ,Withers SB,et al.Mechanistic Links Between Obesity, Diabetes, and Blood Pressure: Role of Perivascular Adipose Tissue [J].Physiol Rev,2019,99(4):1701-1763.[5]Eckel N,Li Y,Kuxhaus O,et al.Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study [J].Lancet Diabetes Endocrinol,2018,6(9):714-724.[6]Mongraw-Chaffin M,Foster MC,Anderson CAM,et al.Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk [J].J Am Coll Cardiol,2018,71(17):1857-1865.[7]Smith GI,Mittendorfer B,Klein S.Metabolically healthy obesity:facts and fantasies [J].J Clin Invest,2019,129(10):3978-3989.[8]Bluher M.Metabolically Healthy Obesity[J].Endocr Rev,2020,41(3):bnaa004.[9]Van Vliet-Ostaptchouk JV,Nuotio ML,Slagter SN,et al.The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies[J].BMC Endocr Disord,2014,14:9.[10]Lavie CJ,Laddu D,Arena R,et al.Healthy Weight and Obesity Prevention: JACC Health Promotion Series [J].J Am Coll Cardiol,2018,72(13):1506-1531.[11]Magkos F.Metabolically healthy obesity: what’s in a name? [J].Am J Clin Nutr,2019,110(3):533-539.[12]Gomez-Zorita S,Queralt M,Vicente MA,et al.Metabolically healthy obesity and metabolically obese normal weight: a review [J].J Physiol Biochem,2021,77(1):175-189.[13]Eckel N,Meidtner K,Kalle-Uhlmann T,et al.Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis [J].Eur J Prev Cardiol,2016,23(9):956-966.[14]Rey-Lopez JP,De Rezende LF,Pastor-Valero M,et al.The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used [J].Obes Rev,2014,15(10):781-790.[15]Liu C,Wang C,Guan S,et al.The Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria [J].Obes Facts,2019,12(1):78-90.[16]Lin H,Zhang L,Zheng R,et al.The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article [J].Medicine (Baltimore),2017,96(47):e8838.[17]Goossens GH.The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function [J].Obes Facts,2017,10(3):207-215.[18]Soriguer F,Gutierrez-Repiso C,Rubio-Martin E,et al.Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study [J].J Clin Endocrinol Metab,2013,98(6):2318-2325.[19]Appleton SL,Seaborn CJ,Visvanathan R,et al.Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study [J].Diabetes Care,2013,36(8):2388-2394.[20]Bray GA,Kim KK,Wilding JPH,et al.Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation [J].Obes Rev,2017,18(7):715-723.[21]Ghiassi S,El Chaar M,Aleassa EM,et al.ASMBS position statement on the relationship between obesity and cancer, and the role of bariatric surgery: risk, timing of treatment, effects on disease biology, and qualification for surgery [J].Surg Obes Relat Dis,2020,16(6):713-724.[22]Mili N,Paschou SA,Goulis DG,et al.Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations [J].Endocrine,2021,74(3):478-497.[23]Neeland IJ,Ross R,Despres JP,et al.Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement [J].Lancet Diabetes Endocrinol,2019,7(9):715-725.

相似文献/References:

[1]蒋 雨,冯 吉,朱和林,等.胃部手术后加速康复与传统康复随机对照的荟萃分析[J].医学信息,2023,36(22):1.[doi:10.3969/j.issn.1006-1959.2023.22.001]
 JIANG Yu,FENG Ji,ZHU He-lin,et al.A Meta-analysis of Randomized Controlled Trials of Accelerated Rehabilitation and Traditional Rehabilitation After Gastric Surgery[J].Journal of Medical Information,2023,36(05):1.[doi:10.3969/j.issn.1006-1959.2023.22.001]

更新日期/Last Update: 1900-01-01